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Tremendous effort has been expended over the past two and a half decades to under-
stand many aspects of camelid heavy chain antibodies, from their biology, evolution, 
and immunogenetics to their potential applications in various fields of research and 
medicine. In this article, I present a historical perspective on the development of camelid 
single-domain antibodies (sdAbs or VHHs, also widely known as nanobodies) since their 
discovery and discuss the advantages and disadvantages of these unique molecules 
in various areas of research, industry, and medicine. Commercialization of camelid 
sdAbs exploded in 2001 with a flurry of patents issued to the Vrije Universiteit Brussel 
(VUB) and later taken on by the Vlaams Interuniversitair Instituut voor Biotechnologie 
(VIB) and, after 2002, the VIB-founded spin-off company, Ablynx. While entrepreneurial 
spirit has certainly catalyzed the exploration of nanobodies as marketable products, 
IP restrictions may be partially responsible for the relatively long time span between 
the discovery of these biomolecules and their entry into the pharmaceutical market. It 
is now anticipated that the first VHH-based antibody drug, Caplacizumab, a bivalent 
anti-vWF antibody for treating rare blood clotting disorders, may be approved and 
commercialized in 2018 or shortly thereafter. This elusive first approval, along with the 
expiry of key patents, may substantially alter the scientific and biomedical landscape 
surrounding camelid sdAbs and pave the way for their emergence as mainstream 
biotherapeutics.
Keywords: camelid single-domain antibody, heavy chain antibody, vHH, nanobody, antibody engineering, 
therapeutic antibody
iNtrODUctiON
The canonical view of antibodies as molecules composed of two heavy chains and two light chains 
was forever changed one day in 1989 following analysis of total and fractionated immunoglobulin 
G (IgG) molecules in the serum of a dromedary camel in the laboratory of Professor Raymond 
Hamers at the Vrije Universiteit Brussel (VUB). The serendipitous discovery of antibodies lacking a 
light chain [heavy chain-only antibodies (HCAbs)] occurred as part of a student-run project aimed 
at developing a serodiagnostic test for trypanosome infection in camels and water buffalos. The pre-
liminary data showed that besides conventional IgG1 (MW ~150 kDa), two other immunoglobulin 
fractions (thereafter called IgG2 and IgG3; MW ~90 kDa) were present which contributed up to 
75% of all serum IgGs (1–3). Comparative studies on the sera of new world camelids (Lama glama 
and Lama pacos) subsequently confirmed the presence of HCAbs, albeit at concentrations between 
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30 and 50% (1, 4–8). Following these exciting findings, it became 
essential to analyze the antigen-binding properties of these IgG 
fractions since the presence of truncated forms of heavy chain 
antibodies with no light chains, classically described as “heavy 
chain disease,” had been reported in human patients (9, 10). No 
functional activity was reported for the pathogenic heavy chain 
antibodies in these patients, as these proteins were shown to 
bear extensive internal deletions in the variable (VH) and the 
first constant region (CH1) domains. By contrast, antibodies 
from camelids exposed to Trypanosoma evansi demonstrated 
strong binding activity in the IgG2 and IgG3 heavy chain-only 
fractions as shown by radio-immunoprecipitation and blotting 
experiments (1).
In two subsequent reports, phage-display technology and 
high-resolution crystallography were utilized to (a) build a 
phage-display library from the lymphocytes of immunized 
camels and isolate monomeric antigen-specific VHH domains 
in the absence of the constant regions (11) and (b) solve crystal 
structures of an unliganded VHH (12) and a VHH:lysozyme 
complex, reported simultaneously by the VUB team and a 
Dutch–French research group (13). The term VHH was originally 
introduced by the VUB team in 1994 to indicate a VH domain 
derived from camelid heavy chain antibodies. The feasibility of 
isolating stable and soluble VHH domains with nanomolar affini-
ties against lysozyme and tetanus toxoid showed very early on 
the promise of these molecules as high-affinity binding moieties. 
Crystallography studies revealed additional salient features of an 
anti-lysozyme VHH, including deep penetration of its long third 
complementarity-determining region (CDR3) into the active site 
of the enzyme; this feature had rarely been seen with conventional 
antibodies and required a fundamental deviation from known 
human canonical CDR1 structure (13). Further evidence of the 
unique antigen recognition behavior of VHH domains (including 
enzyme inhibition) was published over the next several years 
(11, 14, 15), suggesting that VHHs might probe different sets of 
epitopes on proteins compared with conventional antibodies. 
Key proof of concept for producing bivalent/bispecific VHH 
modalities via genetic fusion (using camelid short and long hinge 
sequences) of anti-lyzozyme and/or anti-tetanus toxin VHHs was 
also established very early on (14).
MOLecULAr ONtOGeNY OF cAMeLiD 
HcAbs
Molecular biology techniques were subsequently applied to 
decipher the DNA sequences of HCAbs. The sequencing results 
showed that nature had designed HCAbs as an additional arm 
of the immune systems of camelid ungulates over the course 
of their evolutionary history. The consensus of these studies 
suggested camelid HCAbs possessed: (a) no CH1 domain, and 
therefore, a direct connection of the rearranged VHH exon to the 
hinge region; (b) one of two types of long (IgG2) and short (IgG3) 
hinge isotypes; (c) specific conserved amino acid substitutions 
in framework region 2 (FR2), mainly at VH positions that make 
contact with the VL in classical antibodies, including Kabat 
positions 37, 44, 45, and 47; and (d) potentially different CDR3 
amino acid composition and a broader length distribution for 
CDR3 compared to the heavy chains of conventional antibodies 
(1, 16, 17).
Later genomic studies shed light on the origin of HCAbs in 
dromedary camels and alpacas. It is now established that HCAbs 
are produced from the same igh locus as conventional antibodies 
but with distinct sets of genes for the generation of HCAbs. It 
is estimated that alpaca and dromedary genomes contain ~17 
and ~40 VHH genes, respectively, with an identical organization 
of the genes that produce conventional antibodies (18, 19). 
The CH1 exon is present in the genomic DNA of HCAbs but a 
point mutation (G to A) at the 5′ end of the CH1-hinge intron 
disrupts the consensus splicing site (GT) and causes omission of 
this region during splicing (3, 18, 20–22). A complete picture of 
camelid germline V gene repertoires of heavy and light chains 
and the classification of VH and VHH genes is still missing. 
Published genomic and cDNA data have so far shown that 
camelid VHH genes are highly homologous to the human VH3 
family of clan III with the exception of several key amino acid 
substitutions in FR2, namely, Val37 → Phe/Tyr, Gly44 → Glu, 
Leu45 →  Arg, and Trp47 →  Gly (Kabat numbering), and are 
encoded by a distinct subset of germline V genes. Preliminary 
investigations of published llama VHH sequences classified them 
into four subfamilies by sequence similarity, and many of the 
earliest-described VHH features such as long CDR3s, additional 
disulfide bridges, and particular canonical structures of CDR1–3 
were shown to be subfamily specific (17, 23). Subsequent studies 
in alpaca identified at least three V gene subgroups of the alpaca 
igh locus: IGHV1, IGHV2, and IGHV3 which are equivalent to 
the human IGHV families within clan I (VH families 2, 4, 6), II 
(VH families 1, 5, 7), and III (VH family 3), respectively, based 
on sequence homology. The alpaca VHH genes clustered into six 
subsets by sequence similarity, but all are homologous to human 
IGHV3 genes (18). Furthermore, recent investigations have 
demonstrated the presence of genes belonging to IGHV families 
1, 3, and 4 (human clan I and III) in llama and alpaca, and in 
addition, uncovered new camelid V genes highly homologous to 
the human IGHV5 and IGHV7 families (human clan II); how-
ever, no genes similar to human families 2 or 6 (within human 
clan I) were found (24). Interestingly, a novel promiscuous class 
of V genes in camelids was identified that is closely related to the 
human VH4 family (clan I). These VH4 homologs contribute 
largely to the classical antibody repertoire and lack the hallmark 
solubilizing VHH residues in FR2. Nevertheless, antigen-specific 
VH4-family fragments with VHH-like stability and solubility 
were isolated from an immune llama library (25). In the absence 
of a complete set of camelid germline VH and VHH genes, most 
immunogenetic studies have relied on comparisons with human 
germline genes.
The consensus of immunogenetic studies of camelid HCAbs 
is that repertoire diversification of these molecules may involve 
(a) a large number of unique VHH gene segments recombining 
with DH and JH minigenes, possibly with additional non-
templated nucleotide insertions leading to longer CDR3 loops; 
(b) somatic hypermutation, potentially of extended CDR1 
regions compared with conventional antibodies; (c) acquisition 
of non-canonical cysteine residues in the CDRs and FR2; and 
FiGUre 1 | Chronological timeline of major scientific developments in the field of antibody engineering since the discovery of monoclonal antibodies (mAbs) in 1975 
leading to the regulatory approval of mAbs, antigen-binding fragments (Fabs) and scFvs as therapeutics. Developments for mAbs are shown in orange and 
developments of VHHs/heavy chain-only antibodies (HCAbs) in green. Regulatory approval of the first VHH-based antibody drug is expected in 2018.
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(d) involvement of FR2 residues in antigen binding and in 
structuring the CDR3 loop (3, 22, 26, 27). In agreement with 
immunogenetic analyses, several structural studies have sug-
gested that due to the loss of VL domains, VHH paratopes have 
acquired a higher structural complexity by involving more 
residues in antigen binding compared to classical VHs (27). As 
for the evolutionary origin of HCAbs, it is difficult to draw solid 
conclusions but several hypotheses have been proposed. A com-
mon theme among most of these has been the need for generat-
ing or expanding a new antigen-binding repertoire in Camelidae 
to address certain antigenic challenges, e.g., cryptic epitopes of 
commonly encountered pathogens. Phylogenetic analyses have 
confirmed that HCAbs diverged from conventional antibodies 
as a result of recent adaptive changes (22, 27–29).
HistOrY OF tHe DeveLOPMeNt OF 
cAMeLiD siNGLe-DOMAiN ANtiBODies 
(sdAbs) As tHerAPeUtics
Prior to the discovery of HCAbs, a single report describing the 
concept of sdAbs was published by Sally Ward and colleagues 
in 1989 (30), when they showed that VH domains from an 
immunized mouse, in the absence of a VL domain, could 
bind specifically to lysozyme and keyhole limpet hemocyanin. 
However, poor VH domain stability and solubility, as well as weak 
antigen-binding affinity compared to its fragment variable region 
counterpart (Fv) or to the parent antibody, were major impedi-
ments to any commercial applications (Figure 1).
From a historical perspective, development of camelid 
VHHs as drugs has gone through three major phases. The first 
10 years (1993–2003) can be classified as the exploratory phase, 
which coincided with the founding of Ablynx in December 
2001 as a spin-off company from the Vlaams Interuniversitair 
Instituut voor Biotechnologie. The main developments in the 
first decade included: (i) the first description of VHHs (1); (ii) 
sequence analyses of VHHs with identification of VHH germline 
gene segments and classification of VHH gene subfamilies (16, 
20, 23); (iii) adaptation of phage-display technology to VHHs 
(11) and isolation of antigen-specific VHHs, including several 
enzyme inhibitors (12, 15); (iv) solving the crystal structure of 
several VHH:antigen complexes (13, 31–34); (v) development of 
methods for expression of VHHs in bacteria and yeast systems 
and for biophysical characterization of VHHs (35, 36); and (vi) 
the use of VHHs as reagents in immunoaffinity purification and 
immuno-perfusion (37).
During the second phase of development (2003–2013), VHHs 
began to receive more attention and publications in this area grew 
dramatically, surpassing 1,000 by 2013 [Ref. (38) and personal 
investigation on Web of Science]. Interestingly, a large and diverse 
group of countries and institutions (close to 50) were responsible 
for research on camelid VHHs during this time, mainly for the 
purpose of exploring their potential applications in research, 
biotechnology, and medicine (38). The major hallmark of this 
decade was the start of preclinical and clinical studies of several 
nanobodies by Ablynx and others as therapeutics and imaging 
reagents (39, 40), including VHHs against (i) blood glycoprotein 
vWF to control platelet aggregation and clot formation; (ii) viral 
infection (RSV); (iii) venom toxins; (iv) IL6-R for treatment of 
rheumatoid arthritis; and (v) the use of radiolabeled nanobod-
ies for Her2+ tumor imaging. There were major technological 
advancements made in the expression of VHHs in heterologous 
systems and in creating an array of bi- and multivalent VHHs with 
superior efficacy during this decade.
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Now in the third phase of development (2014–present), 
publications continue to grow and more VHHs have entered into 
clinical trials or advanced closer to the market. The main patent 
claims on camelid antibody fragments expired in the summer of 
2014 in Europe and in the summer of 2017 in America. Ablynx 
has expanded its collaborations with large biophama players, 
such as Merck, Boehringer Ingelheim, Sanofi, and so on, with 
more than 20 preclinical and clinical programs. It is expected 
that the first VHH-based drug (Caplacizumab; bivalent anti-vWF 
nanobody for treating rare blood clotting disorders) will reach 
the market sometime in 2018 (www.ablynx.com). Meanwhile, IP 
limitations on the composition of matter of VHHs are diminishing 
and more biotechnology companies (39) are showing interest in 
commercialization of these domain antibodies as therapeutics, 
diagnostics, and research reagents (Figure 1).
cAMeLiD sdAbs: PrOs, cONs, AND 
APPLicAtiONs
Immunization of Camelidae against targets of interest leads to 
the in  vivo maturation of HCAb and conventional antibody 
repertoires. Construction of phage-display libraries is performed 
by cloning of amplified VHH repertoires with minimal modifica-
tion, thus presenting an authentic picture of in  vivo-matured 
heavy chain repertoire diversity. By contrast, in both scFv librar-
ies (requiring the artificial joining of VH and VL domains by a 
synthetic linker) and antigen-binding fragment (Fab) libraries 
derived from conventional antibody repertoires, natural VH–VL 
pairings are usually lost. The potential for direct cloning of VHH 
repertoires from immunized camelids, the smaller library sizes 
required to capture the immune VHH repertoire, the stability 
of the libraries, the feasibility of displaying VHHs on a phage 
or alternative display formats, and the ease of sub-cloning and 
expression of antigen-specific VHHs are among the major techni-
cal advantages of the camelid VHH platform over conventional 
antibody platforms.
Key characteristics of VHHs include their high affinity and 
specificity (equivalent to conventional antibodies), high thermo-
stability, good solubility and strictly monomeric behavior, small 
size (2.5 nm in diameter and about 4 nm in length; ~15 kDa), 
relatively low production cost, ease of genetic engineering, for-
mat flexibility or modularity, low immunogenicity, and a higher 
penetration rate into tissues (3, 41–44). The short half-life of 
VHHs in blood circulation is well suited to certain applications 
such as tumor imaging or delivery of toxin or radioisotopes to 
diseased tissues where rapid clearance is required. However, 
the pharmacokinetic behavior of VHHs can also be improved 
by extending their half-lives using different formatting options, 
including PEGylation or fusion to serum albumin or an anti-
serum albumin moiety (43, 45, 46). The immunogenicity of 
VHHs domains can also be minimized by humanization (47–49). 
As with all antibodies of non-human species origin (and even 
fully human antibodies), immunogenicity and toxicity must be 
investigated empirically for humanized VHHs. A complete pic-
ture of the immunogenicity of non-humanized and humanized 
camelid VHHs is lacking due to insufficient data, but anti-drug 
immune responses may have been a major reason for the clinical 
failure of a humanized tetravalent Nanobody®targeting the DR5 
receptor (50). As of 2016, VHHs have been isolated against more 
than 120 therapeutically important targets relevant to oncology, 
in  vivo imaging, hematology, infectious diseases, neurological, 
and inflammatory disorders, with some in advanced stages of 
clinical trials (39).
One of the unique characteristics of VHHs is their ability 
to target antigenic epitopes at locations which are difficult to 
access by large molecules such as conventional monoclonal 
antibodies (mAbs). Examples include intracellular targets (51, 
52) or epitopes concealed from mAbs in protein structures 
(53), G protein-coupled receptors (54, 55), and ion channels 
(3). VHHs are ideally suited for such applications due to their 
small size, target specificity, and long CDR3 loops, bypassing 
many drawbacks related to small-molecule synthetic drugs such 
as fine specificity and off-target toxicity (56). As “intrabodies,” 
VHHs are also ideally suited for cytosolic expression due to their 
ability to fold in the reducing intracellular environment. This 
feature likely reflects the single disulfide linkage present in the 
VHH domain, as compared to the multi-domain structure and 
multiple disulfide linkages of conventional antibodies, and may 
not be completely general to all VHHs but appears to be quite 
common; intracellular expression of VHHs has been widely and 
productively exploited for in  vivo cellular imaging (5, 57) as 
well as to inhibit the function of viral proteins (58, 59). There 
have been several excellent reviews covering VHH applications 
in different areas of basic and applied research and a detailed 
description of each application is beyond the scope of this article 
(3, 39, 41, 43, 57, 60–65).
VHHs are also well suited in the generation of bi- and multi-
specific antibodies. In the field of antibody therapeutics, it is now 
widely accepted that monotherapy of cancer and other diseases 
may not result in effective outcomes, in particular due to the 
problem of acquired resistance (66, 67). Bispecific antibodies 
provide a possible solution in which they could bind simulta-
neously to a tumor-associated antigen and another activating 
molecule, e.g., CD3 on T  cells, leading to tumor killing/lysis 
through lymphocyte recruitment, or alternatively, could target 
two or more tumor epitopes (bi-paratopic) or antigens simulta-
neously. Bispecific VHHs may be uniquely positioned for these 
applications given their simple design and small size relative 
to other antibody fragments, which may result in better solid 
tumor penetration rates, homogeneous production at high yield 
in microbial systems, and ease of fusion to a heterodimeriza-
tion motif, therefore bypassing issues related to some linker 
peptides such as aggregation and immunogenicity (45, 66, 68, 
69). Interestingly, all of the VHH-based therapeutic candidates 
in clinical trials are composed of bivalent, trivalent, or higher 
valency formats (39). It has been shown that some VHHs, when 
properly selected, are able to transmigrate through human brain 
endothelial cell layers spontaneously and, possibly through 
a receptor-mediated process (70–72); bispecific molecules 
incorporating these VHHs can, thus, deliver attached cargo (e.g., 
therapeutics) into the brain in rodents (73).
Despite the many advantages of VHHs, there are several draw-
backs to be considered as well. The fact that the antigen-binding 
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paratope of camelid HCAbs has been restricted to a single 
domain of about 110 amino acids will automatically put more 
weight on each and every residue in the VHH domain. The 
extended CDR1, longer CDR3, involvement of FR2 in antigen 
binding and shaping the CDR3 loop, the role of the “CDR4” 
(residues 76–80) loop in antigen binding, and extensive somatic 
hypermutation are some of the evolutionary mechanisms 
adapted to compensate repertoire diversity due to the lack of 
a VL domain (3). Therefore, there may be limitations on the 
extent of manipulation and engineering that can be tolerated 
by antigen-specific VHHs. For example, complete humanization 
of camelid VHHs involving the mutation of residues outside the 
antigen-binding loops often drastically compromises antigen-
binding affinity, VHH stability, and the expression yield (unpub-
lished data). A survey of the literature clearly demonstrates that 
almost all VHHs isolated to date have originated from direct 
camelid immunization, or from large naïve camelid libraries, 
although recently, successful isolation of VHHs from synthetic 
or semi-synthetic libraries against a number of protein antigens 
has also been reported (74–77). All available pieces of evidence 
support the notion that the VHH domain is a highly complex 
molecule and that each amino acid (depending on its position) 
may have direct and indirect effects on the molecule’s stability 
and structural integrity, as well as on antigen-binding affinity 
and specificity.
Another limitation of VHHs is their low propensity to bind 
small molecules, likely due to their dominant convex surface 
topology as compared to the flat or concave topologies found on 
conventional antibody fragments (e.g., scFv, Fab). In a number 
of llama immunization trials, we and others have been able to 
generate strong conventional immune responses, but rather 
weak HCAb responses, against several haptens and carbohydrate 
antigens (unpublished data). However, repeated immunization of 
camelids with small molecules conjugated or fused to larger pro-
teins has led to the successful isolation of VHHs against caffeine 
(78), red dye (79), and linear peptides (80, 81) with affinities rang-
ing from micromolar to low nanomolar. The biophysicochemical 
properties of VHHs suggest that they would be well suited to many 
immunodiagnostic platforms for detecting small molecules and 
environmental chemicals; however, isolation of high-affinity 
VHHs suitable for such applications seems to be a difficult task, 
although not impossible (3, 64, 65, 78, 82, 83). Immunization of 
large animals and heterogeneity in immune responses among 
individual outbred animals is another consideration which is 
important when alternative immunization techniques such as 
DNA immunization are applied. DNA immunization has had 
limited success in camelid and other large animals and reproduc-
ibility is often a major issue to be tackled (84–87). To overcome 
this limitation, transgenic mice bearing either a rearranged 
dromedary γ2a chain or hybrid llama/human antibody loci have 
been generated that produce a form of dromedary or human 
heavy chain antibodies (88–90).
cAMeLiD sdAbs versUs mAbs
The first therapeutic mAb, Orthoclone OKT3, a murine IgG2a 
for the prevention of kidney transplant rejection, hit the market 
little more than a decade after the discovery of hydridoma 
technology in 1975 (91–94). Currently, mAbs constitute about 
half of marketed biological products and, as of January 2017, 68 
mAbs have been approved by the Food and Drug Administration 
(FDA) in the USA and/or by the European Medicine Agency 
(EMA) in Europe. The projected global sales of mAbs will be 
close to $100 billion in 2017 (44, 95). The lack of restrictive IP 
on the original technology is considered by many as a driving 
force that allowed researchers to develop effective research 
tools and diagnostic mAb-based reagents without limitation. 
The introduction of antibody fragments, such as Fab and scFv 
(the “second generation” of antibodies), combined with the 
power of phage-display technology in the late 1990s, opened 
new horizons in the world of antibodies and empowered 
researchers with the ability to clone the entire immunoglobulin 
repertoire of mammalian immune B cells and to isolate specific 
antibody fragments virtually against any target (96–98). This 
technology led to the development of the first FDA-approved 
fully human mAb, Humira, which was obtained from a phage-
displayed human antibody library 12  years after the initial 
paper by McCafferty and co-workers on the construction of 
phage-displayed human antibody libraries (99–101). Further 
developments in antibody engineering have so far resulted in 
three FDA-approved therapeutic Fabs (95).
Overwhelming evidence in the literature suggests that 
camelid VHHs, as the so-called “third generation” of antibodies, 
have many added features that supersede those of conventional 
mAbs and antibody fragments (Fab and scFv). Although VHHs 
have already been commercialized for non-medical applica-
tions (63, 102), the research and medical communities eagerly 
await the first VHH-based therapeutic to gain approval. If we 
consider the 9- to 13-year time span between the discovery of 
the key technology enabling conventional mAbs (hybridoma 
technology) and the FDA-approval of a mAb or an antibody 
fragment, a longer time has been required for the development 
of the first VHH-based therapeutic. It is unclear if technical 
challenges, regulatory hurdles, or the need to define a unique 
niche/indication for VHHs, have been involved in the prolonged 
delay of the first VHH-based therapeutic. It is obvious that issues 
related to downstream processing, stability, immunogenic-
ity, toxicity, safety, and potency of a VHH-based therapeutic 
product will be doubly scrutinized by FDA and EMA since it 
would represent the first product of its kind to enter the market. 
The fact that the first potential Ablynx product is an engineered 
bivalent anti-vWF nanobody and is produced in a microbial 
system may have raised additional red flags for the approving 
regulatory bodies.
cONcLUDiNG reMArKs
Over a quarter century has passed since the first observation 
by Hamers and colleagues of camelid HCAbs. This finding was 
a significant milestone in the field of antibody engineering and 
opened many new opportunities and applications. It was also 
instrumental in reviving the concept of sdAbs, which had been 
originally suggested by Ward et al. a few years earlier. The unique 
and extraordinary features of HCAbs and their antigen-binding 
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domains (VHHs) have with no doubt attracted many researchers 
and commercial entities to the field of antibody engineering. VHHs 
are now closer than ever to approval as pharmaceutical drugs to 
fight a wide range of diseases, including cancer, inflammation, 
hematology, and respiratory diseases, with five VHH-based drugs 
in various stages of clinical development. VHHs have also been 
shown to be effective as therapeutics against infectious disease, 
particularly in viral therapy, as well as robust reagents in the field 
of diagnostic and imaging applications. While the commercial 
applications of VHHs have been slowed by IP limitations, it is 
probable that demand, as well as extensive research on these 
antibody domains, will ultimately supersede these limitations and 
bring many more of these molecules into use as biopharmaceuti-
cal reagents within the next decade.
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